Nick Naclerio, Founding Partner of Illumina Ventures, will be at the AGBT Meeting General Meeting in Marco Island, Florida! This premier event unites global leaders to drive breakthroughs in genome biology, forge partnerships, and shape the future of genomics. agbt.org/home/home/gene…

🎉 Congrats to portfolio company LetsGetChecked on receiving FDA clearance for the ImPress lancing device. 👏 We’re excited to see how ImPress will empower people to take control of their health! Learn more: businesswire.com/news/home/2025… #PartnerNews #diagnostics

Our Partner Ron Mazumder will be at the Biocom California Global Life Science Partnering & Investor Conference tomorrow at LodgeTorreyPines. He looks forward to learning key trends, seeing cutting-edge technologies and engaging with industry leaders. More: biocom.org/conferences/gl…

On Wed, 3/5 at 8:10 am PT, join Illumina Ventures Partner Mara Aspinall at the virtual Main Stage for a keynote on “The Power and Potential of Point-of-Care Diagnostics” at The State of Precision Medicine 2025, hosted by Inside Precision Medicine. Register for free here: webinars.liebertpub.com/e/The-State-of…

Tucson Lifestyle’s Women Visionaries feature is live! Our Partner Mara Aspinall shares how her passion for diagnostics & genomics has shaped her career—from leading Ventana Medical / Roche to investing in the future of precision medicine.📖More on page 77: tucsonlifestyle-az-bb.newsmemory.com

Charles Lin, PhD, & Charles White, PhD, will be at World Agri-Tech in San Francisco on 3/11-12! Excited to connect with agtech leaders driving innovation. #WorldAgriTech Learn more: worldagritechusa.com

Heading to Precision Med #TRICON in San Diego? Catch Partner Mara Aspinall at two key sessions: 📅 3/11 | 3:40 PM PT – Driving Innovation in Precision Medicine 📅 3/12 | 8:00 AM PT – Investing in Precision Medicine More info: triconference.com Precision Med TRI-CON

.DNA Script, EVA Pharma & Quantoom are building a system to produce 100M+ RNA vaccine doses annually. With enzymatic #DNAsynthesis, automation & #AI, they aim to accelerate access & make Africa vaccine self-sufficient by 2040. See in Genetic Engineering & Biotechnology News: genengnews.com/topics/bioproc… #PartnerNews

Wrapping up an incredible week at #PrecisionMed #TRICON! Founding Partner Nick Naclerio & Partner Mara Aspinall led great discussions on investing in precision medicine & managing growth. Thanks to all who joined us! Let’s keep the conversation going: illuminaventures.com/contact/.

Portfolio company Arbor Biotechnologies announced the closing of a $73.9M #SeriesC financing round to support the advancement of its novel #GeneEditing therapeutics pipeline. Learn more: arbor.bio/arbor-biotechn…

Portfolio company AlamarBio announced its first five distribution partners, expanding commercial support in the Asia-Pacific region. This will increase global access to proteomics solutions for biomarker discovery & disease! Learn more: alamarbio.com/alamar-bioscie… #PartnerNews

Illumina Ventures portfolio company AlamarBio launched its #NULISAseq Mouse Panel 120! With a small sample, scientists can study protein expression in mice across key biological processes including neuro targets & immunology. Explore the panel: alamarbio.com/products-and-s…

Nick Naclerio, Founding Partner of Illumina Ventures, will be at the @AGBT Agricultural meeting in Orlando, Florida, today-April 2! This event unites global leaders to drive collaboration and tackle ag challenges facing our planet. Learn more: agbt.org/home/home/agri… #AGBT

Portfolio company Arima Genomics highlighted research using its Hi-C technology identifying SCML2 and CTCF as key regulators of sperm differentiation. This can help scientists explore therapies for male infertility. Case study: arimagenomics.com/resources/blog… #PartnerNews

Following IND approval by the FDA in December 2024, the redePHine Phase 1/2 study of investigational therapy ABO-101 is now open and enrolling patients with PH1 in the United States. Learn more about the study: clinicaltrials.gov (NCT06839235)

Portfolio company LetsGetChecked announced its hereditary cancer solution that advances genetic screening by identifying risks associated with cancer, empowering individuals and providers to make informed healthcare decisions. More details: businesswire.com/news/home/2025… #PartnerNews

CEO Spotlight: Rémi Dangla of our portfolio company Stilla Technologies, discusses the company’s rapid advancements in #oncology research and cell and gene therapy, as well as insights on the recent merger with Bio-Rad. illuminaventures.com/resource/news/… #PartnerNews

🚨Our Multi-Omics Grant Program is now open! 🧬 Get up to $10,000 in kits & services to integrate 3D genomics into your multi-omics research. Learn more & apply today: hubs.la/Q03gY38Z0 #MultiOmics #ResearchGrant #3DGenomics

Portfolio company Attovia Therapeutics closed a $90M Series C! Funds will advance its ATTOBODY™ pipeline, incl. ATTO-1310  & ATTO-3712. Big strides in immune-mediated disease! More: globenewswire.com/news-release/2… #PartnerNews

Illumina Ventures Partner Tom Willis, PhD, will be attending the AACR Oncology Industry Partnering Event, April 24-25 in Chicago. Let us know if you’ll be there and learn more: aacr.org/meeting/aacr-o… #AACR25 #cancer #oncology